Last reviewed · How we verify
Iron Sucrose IV
Iron sucrose delivers iron as a stable complex that is absorbed and utilized by the body to replenish iron stores and support hemoglobin synthesis.
Iron sucrose is a stable iron-carbohydrate complex that delivers iron directly into the bloodstream to replenish iron stores and support hemoglobin synthesis. Used for Iron deficiency anemia in patients with chronic kidney disease, Iron deficiency anemia in hemodialysis patients, Iron deficiency anemia in peritoneal dialysis patients.
At a glance
| Generic name | Iron Sucrose IV |
|---|---|
| Also known as | Iron Sucrose injection |
| Sponsor | CN NGANOU-GNINDJIO, MD, MSc |
| Drug class | Iron replacement agent |
| Target | Transferrin receptor (indirect); iron supplementation |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Iron sucrose is a polynuclear iron(III) hydroxide sucrose complex that provides bioavailable iron for erythropoiesis. When administered intravenously, the complex is taken up by macrophages and transferred to transferrin for transport to bone marrow erythroid precursors, where it is incorporated into hemoglobin. This formulation reduces gastrointestinal side effects associated with oral iron and provides rapid iron repletion in patients with iron deficiency anemia, particularly those with chronic kidney disease or intolerance to oral iron.
Approved indications
- Iron deficiency anemia in patients with chronic kidney disease (CKD), including those on hemodialysis and peritoneal dialysis
- Iron deficiency anemia in non-dialysis CKD patients
- Iron deficiency anemia in patients intolerant or unresponsive to oral iron therapy
Common side effects
- Hypotension
- Headache
- Nausea
- Vomiting
- Abdominal pain
- Diarrhea
- Injection site reactions
Key clinical trials
- Iron and Immune Response to Vaccine (IRONMUM) (NA)
- Comparison of the Mean Change in Hemoglobin With Ferric Carboxymaltose and IV Iron Sucrose in Anemic Antenatal Patients (NA)
- Comparison of Oral Iron With IV Iron in Patients With Anemia of Chronic Renal Failure Not on Dialysis (PHASE3)
- Ferric Carboxymaltose Versus Iron Sucrose for Treating Anemia in Pregnant Women (PHASE4)
- Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy (PHASE2)
- Effect of the Combined Programme on Perioperative Anaemia（CPPA） (NA)
- Intravenous Iron Sucrose for Acute Decompensated Heart Failure Patients With Reduced Ejection Fraction and Iron Deficiency (PHASE4)
- Oral Liposomal Iron Versus Injectable Iron Sucrose for Anemia Treatment in Non-Dialysis Chronic Kidney Disease Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iron Sucrose IV CI brief — competitive landscape report
- Iron Sucrose IV updates RSS · CI watch RSS
- CN NGANOU-GNINDJIO, MD, MSc portfolio CI